Ballwin, MO, United States of America

Canxin Xu

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:

goldMedal1 out of 832,966 
Other
 patents

Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Profile of Inventor Canxin Xu**

Introduction

Canxin Xu is an innovative inventor based in Ballwin, Missouri, USA. He has made significant contributions to the field of pharmaceuticals through his inventive work in developing new compounds.

Latest Patents

Canxin Xu holds a patent for his invention titled "Substituted pyrrolopyridines as JAK inhibitors." This patent includes novel pyrrolopyridine compounds characterized by specific structural formulas, which are defined in detail. The application of these compounds extends to pharmaceutical compositions aimed at treating various diseases, including pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo, and psoriasis. Additionally, this invention provides methods for inhibiting JAK kinase activity in both human and animal subjects.

Career Highlights

Throughout his career, Canxin Xu has demonstrated expertise and a strong commitment to advancing medical treatments. His research has led to the development of cutting-edge solutions that aim to improve patient outcomes through innovative drug therapies.

Collaborations

Canxin has had the opportunity to work alongside talented individuals such as Eric Jon Jacobsen and David R Anderson. These collaborations highlight the importance of teamwork and shared knowledge in the development of new medical innovations.

Conclusion

With a focus on enhancing therapeutic options for complex diseases, Canxin Xu’s patent reflects his dedication to the field of pharmaceutical innovations. His work contributes to a broader understanding of JAK inhibitors and their potential in treating a variety of conditions, underscoring the importance of creativity and research in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…